
Criteria for IRB Approval of Research

Bertha deLanda Research Compliance Office December 2010



"Creation of new knowledge is good, but an optional good."

"Respect and care for human beings is good – a mandatory good."

Hans Jonas

"All (IRB) members should review enough information so that they will be able to determine whether the research meets the regulatory criteria for approval."





AAHRPP Element II.2.D

Criteria for Approval of Research

45 CFR 46.111 (a) (OHRP) and 21 CFR 56.111


"In order to approve research covered by these regulations the IRB shall determine that all of the following requirements are satisfied..."

We derive our criteria from federal regulations

Criteria for Approval of Research	
Risk	Risks to participants
Selec	Selection of subjects
etc	When appropriate



Risks to subjects are minimized



1. by using procedures consistent w/ sound research design

- 2. by using procedures that do not involve **unnecessary risk**
- 3. when appropriate, by using diagnostic or treatment procedures already being performed

eProtocol 2, 8(c)-(f), 9





Risks to subjects are reasonable in relation to anticipated benefits

eProtocol 1(b), 9,10

<u>Should consider</u>: only risks/benefits which may result from <u>research</u> e.g., CAT scan







Importance of the resulting knowledge



Should not consider:

Possible long-range effects of applying knowledge gained in the research

e.g., what if researcher was investigating the nutritional value of genetically altered vegetables?





Importance of the resulting knowledge



IRB cannot consider the resulting effects of the research on public policies







- Selection of subjects is equitable
 IRB must take into account:
 - Purpose of the research
 - Setting where it is conducted
- Vulnerable populations:
 - Children
 - Prisoners
 - Mentally disabled



e.g., 90% of all new drugs tested prior to 1970 were done on prisoners

e.g., testing a new flu vaccine on only adult males
 eProtocol 1(a), 2(a)(b), 8(a)-(f), 9(f) Research Compliance Office



The IRB may approve a consent procedure which waives or alters some or all of the elements of informed consent

Informed consent must be:

Obtained from each subject or a legally authorized representative





eProtocol 13

Research Compliance Office

Informed consent must be:

Appropriately documented

The IRB may approve a procedure which waives the documentation (signature) for informed consent





eProtocol 13

Research Compliance Office

...and when appropriate...



6. Data collection is monitored to ensure subject safety

IRB requires plan for > minimal risk studies **NIH** requires DSMB for Phase III clinical trials

eProtocol 9(c)(e)

When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.

...and when appropriate...

7. Privacy/confidentiality is protected



eProtocol 9(c)(e)

When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.

...and when appropriate... Additional safeguards for vulnerable populations

46.111 (b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence...

FDA-regulated research only: FDA includes "handicapped" in the list of vulnerable subjects. Stanford University includes students, employees and laboratory personnel as a vulnerable population











eProtocol 9(f) 14

Research Compliance Office



Purpose:

 Aids the primary reviewer(s) in summarizing review of a protocol

✓ Used as a tool for presentation during panel meetings

Self-populating; editing and additions are made as necessary

✓ Satisfies some of the important elements pertaining to a complete review

Reviewer Checklist	Protocol ID : Disney Jr., Leland Title : MED-REG	₽
	Medical REGUL	AR_8_0
Reviewer Checklist Print View	AB C D-E F-G H-I J-K L M N A. Purpose of Study (eProtocol question 1a) Consider: . . Is the study likely to achieve its aims? Ves, this study is being conducted by a qualified staff using previous approved treatments. This study is also a collaboration with an infamiliar with this type of research.	Isly
	B. Brief Description of Study (eProtocol question 2a) Consider:	
	 Are procedures consistent with sound study design? 	
	This study has gone through scientific and scholarly review via CC'	го.
	Research Compliance Office	16